Vice Chancellor Paul Fioravanti has determined the head of a pain management drug developer breached contracts with a Sorrento Therapeutics-backed company by diverting opportunities and trade secrets to a newly formed competitor.

The Sept. 1 post-trial decision to hold Anthony Mack and Virpax, the West Chester, Pennsylvania-based company for which Mack is the chairman and CEO, liable is a win for the Latham & Watkins and Morris, Nichols, Arsht & Tunnell team that represented Sorrento and Scilex Pharmaceuticals, though Fioravanti has asked for additional briefing to determine what remedy he’ll grant.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]